Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Non-Current Debt: 2022-2025

Historic Non-Current Debt for UroGen Pharma (URGN) over the last 4 years, with Sep 2025 value amounting to $122.1 million.

  • UroGen Pharma's Non-Current Debt rose 0.33% to $122.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.1 million, marking a year-over-year increase of 0.33%. This contributed to the annual value of $121.7 million for FY2024, which is 23.52% up from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Non-Current Debt is $122.1 million, which was down 0.32% from $122.5 million recorded in Q2 2025.
  • UroGen Pharma's 5-year Non-Current Debt high stood at $122.5 million for Q2 2025, and its period low was $70.8 million during Q1 2022.
  • Moreover, its 3-year median value for Non-Current Debt was $98.6 million (2023), whereas its average is $109.0 million.
  • In the last 5 years, UroGen Pharma's Non-Current Debt skyrocketed by 38.34% in 2023 and then fell by 0.49% in 2024.
  • UroGen Pharma's Non-Current Debt (Quarterly) stood at $97.5 million in 2022, then rose by 1.04% to $98.6 million in 2023, then climbed by 23.52% to $121.7 million in 2024, then increased by 0.33% to $122.1 million in 2025.
  • Its last three reported values are $122.1 million in Q3 2025, $122.5 million for Q2 2025, and $122.1 million during Q1 2025.